1. Home
  2. TSCO vs BIIB Comparison

TSCO vs BIIB Comparison

Compare TSCO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tractor Supply Company

TSCO

Tractor Supply Company

HOLD

Current Price

$54.03

Market Cap

27.0B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$171.27

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSCO
BIIB
Founded
1938
1978
Country
United States
United States
Employees
N/A
N/A
Industry
RETAIL: Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.0B
24.2B
IPO Year
1994
1991

Fundamental Metrics

Financial Performance
Metric
TSCO
BIIB
Price
$54.03
$171.27
Analyst Decision
Buy
Buy
Analyst Count
20
23
Target Price
$63.00
$179.48
AVG Volume (30 Days)
6.7M
1.4M
Earning Date
01-29-2026
02-06-2026
Dividend Yield
1.72%
N/A
EPS Growth
0.57
N/A
EPS
2.07
10.97
Revenue
$15,399,257,000.00
$10,065,900,000.00
Revenue This Year
$7.29
$3.56
Revenue Next Year
$6.51
N/A
P/E Ratio
$25.81
$15.84
Revenue Growth
4.26
4.77
52 Week Low
$46.85
$110.04
52 Week High
$63.99
$190.20

Technical Indicators

Market Signals
Indicator
TSCO
BIIB
Relative Strength Index (RSI) 61.66 45.71
Support Level $50.18 $160.36
Resistance Level $51.98 $175.29
Average True Range (ATR) 1.37 6.18
MACD 0.45 -1.26
Stochastic Oscillator 81.82 35.48

Price Performance

Historical Comparison
TSCO
BIIB

About TSCO Tractor Supply Company

Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,364 of its namesake banners in 49 states, along with 206 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2024, revenue consisted primarily of livestock, equine & agriculture (26%), companion animal (25%), and seasonal & recreation (23%).

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: